100 top cell and gene therapy companies to watch in 2023

[Image courtesy of ipopba/Adobe Stock]

The cell and gene therapy sector is poised to deliver a wave of new therapies that could potentially cure rare and common diseases. As many as 13 new cell or gene therapies could be approved for use in the U.S., Europe, or both by the end of 2023.

While manufacturing and regulatory challenges remain, the cell and gene therapy industry continues to offer significant therapeutic potential and commercial opportunities.

This year, we have beefed up our list of leading cell and gene therapy companies, doubling the number of organizations from 50 to 100.

In selecting the companies for this list, we weighed public companies’ degree of involvement in cell and gene therapy, including drug developers, equipment vendors and CDMOs specializing in the area. For private companies, we factored in their funding levels, pipeline and degree of history for the list.


Read more
  • 0

OrbiMed taps former Moderna CMO and Gossamer Bio co-founder

The healthcare investment firm OrbiMed (New York City) has added two members to its team, including Dr. Tal Zaks, the former chief medical officer (CMO) at Moderna. Zaks will be a venture partner at Orbimed. Also joining the firm is Dr. Sheila Gujrathi, who was formerly the CEO of Gossamer Bio, who will be a venture advisor at OrbiMed.

Dr. Tal Zaks

Zaks spent six years at Moderna, where he was involved in the company’s metamorphosis from private biotech to COVID-19 vaccine pioneer with a sizable research pipeline in multiple therapeutic areas.

As for Gujrathi, she has experience in various companies, including Receptos, which Celgene acquired in 2015. She has also worked as a physician and management consultant at McKinsey and held several other leadership positions. Gujrathi also serves as the director of the board at Janux Therapeutics, chair of the board of directors at ADARx Pharmaceutics an…

Read more
  • 0